
Conference Coverage
about 2 months ago
Top 5 Takeaways From EHA 2026 That Patients Should KnowLatest Content

When Insurance Denies Cancer Treatment: Finding Strength and Resilience After an Appeal Is Rejected

9 Months After Surgery: Carolyn Rothfeld's Lung Cancer Story

How Robotic Surgery Advances Have Enhanced Recovery in Patients With Lung Cancer

After Breast Cancer, Finding the Time and Space to Live Again

What Does a High-Risk Multiple Myeloma Diagnosis Mean?

Shorts










Podcasts
Videos
All News

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life.

Learn how Talvey plus Tecvayli cut the risk of myeloma progression or death by 89%, how the combination is given and what it may mean for daily life.

Dr. Mark Zhao explains how minimally invasive techniques preserve function, speed recovery and why patients should not wait years to raise bowel symptoms with their doctor.

Six years after follicular lymphoma treatment, a follow-up CT scan brought encouraging news—but the fear of recurrence and uncertainty still linger.

Luciana Lopes Manfredini, of Einstein Hospital Israelita in São Paulo, Brazil, developed a triage scale for emergency cancer patients now being adopted across North and Latin America.

Melanie Diaz, DNP, NP-C, OCN, of St. Francis Cancer Institute, blends firm accountability with deep empathy to keep cancer patients engaged and empowered throughout treatment.

Diagnosed with limited-stage small-cell lung cancer, Tammy shares how treatment progress and a mindset shift helped her find hope.

The 10-3 vote came during a discussion in which the limitations of TIL therapy, the only approved option for this group of patients, were raised repeatedly.

The FDA approved Pluvicto with hormone therapy for PSMA-positive metastatic prostate cancer, helping delay disease progression in patients.

Patients with advanced biliary tract cancer lived longer on Imfinzi (durvalumab) plus chemotherapy than on chemotherapy alone, according to four-year follow-up data from the phase 3 TOPAZ-1 trial.

Tafinlar plus Mekinist extended progression-free survival to 12.8 months vs. 3.7 months with placebo in BRAF V600E-positive thyroid cancer.

After surviving testicular cancer, one survivor shares how writing, faith, running and hope helped him heal and embrace a meaningful life after treatment.

Heather Prather shares her stage 4 non small cell lung cancer journey, finding hope, joy and support through the LiveLung community and cancer advocacy.

A simple balance exercise for cancer patients: the Drinking Bird. Learn how this single-leg move builds stability, strength, and confidence safely.

After 12 years cancer-free, a breast cancer survivor reflects on how her diagnosis inspired her daughters to make informed choices about their health.




















